Key Highlights: Implications: For Novartis India, bringing these brands back in‑house supports a more controlled go‑to‑market under new PE ownership and aligns with its plan to insta...
Key Highlights: Implications: The deal adds ~$90–100 million of annualized revenue visibility from 2029, diversifies Gland’s customer base, and strengthens its credibility as a o...
Key Highlights: Implications: The collaboration gives Arica Pharmaceutical a potential growth catalyst as it moves beyond its core anti-diabetic, neurosciences, and cardiovascular portfolio...
Key Highlights: Implications: Pivot Path’s majority sale to an Ascent-led consortium effectively spins it out as an independent, PE-backed specialist, which should accelerate its growth in...
